دورية أكاديمية
أعرض في EDS

When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.

التفاصيل البيبلوغرافية
العنوان: When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.
المؤلفون: Callenbach MHE; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, The Netherlands., Vreman RA; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, The Netherlands.; National Health Care Institute (ZIN), 1112 ZA Diemen, The Netherlands., Mantel-Teeuwisse AK; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, The Netherlands., Goettsch WG; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, The Netherlands.; National Health Care Institute (ZIN), 1112 ZA Diemen, The Netherlands.
المصدر: International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Dec 26; Vol. 20 (1). Date of Electronic Publication: 2022 Dec 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI, c2004-
مواضيع طبية MeSH: Motivation*, Netherlands ; Surveys and Questionnaires
مستخلص: This study aimed to identify the current experiences with and future preferences for payment and reimbursement models for high-priced hospital therapies in the Netherlands, where the main barriers lie and assess how policy structures facilitate these models. A questionnaire was sent out to Dutch stakeholders (in)directly involved in payment and reimbursement agreements. The survey contained statements assessed with Likert scales, rankings and open questions. The results were analyzed using descriptive statistics. Thirty-nine stakeholders (out of 100) (in)directly involved with reimbursement decision-making completed the survey. Our inquiry showed that currently financial-based reimbursement models are applied most, especially discounts were perceived best due to their simplicity. For the future, outcome-based reimbursement models were preferred, particularly pay-for-outcome models. The main stated challenge for implementation was generating evidence in practice. According to the respondents, upfront payments are currently implemented most often, whereas delayed payment models are preferred to be applied more frequently in the future. Particularly payment-at-outcome-achieved models are preferred; however, they were stated as administratively challenging to arrange. The respondents were moderately satisfied with the payment and reimbursement system in the Netherlands, arguing that the transparency of the final agreements and mutual trust could be improved. These insights can provide stakeholders with future direction when negotiating and implementing innovative reimbursement and payment models. Attention should be paid to the main barriers that are currently perceived as hindering a more frequent implementation of the preferred models and how national policy structures can facilitate a successful implementation.
References: Niger Postgrad Med J. 2015 Oct-Dec;22(4):195-201. (PMID: 26776330)
Health Policy. 2018 Mar;122(3):230-236. (PMID: 29373186)
Value Health. 2020 Apr;23(4):425-433. (PMID: 32327159)
Value Health Reg Issues. 2019 Sep;19:122-131. (PMID: 31416014)
Health Policy. 2020 Sep;124(9):959-964. (PMID: 32616313)
J Manag Care Spec Pharm. 2017 Oct;23(10):1084-1090. (PMID: 28944726)
Health Policy. 2017 Apr;121(4):354-362. (PMID: 28238340)
Appl Health Econ Health Policy. 2017 Feb;15(1):5-11. (PMID: 27581118)
J Health Serv Res Policy. 2015 Jan;20(1):52-9. (PMID: 25092883)
Pharmacoeconomics. 2021 Sep;39(9):1021-1044. (PMID: 34231135)
Health Policy. 2019 Mar;123(3):267-274. (PMID: 30316540)
Value Health Reg Issues. 2018 Sep;16:33-38. (PMID: 29936067)
Health Econ Rev. 2020 May 21;10(1):13. (PMID: 32440753)
Clin Pharmacol Ther. 2022 Jan;111(1):52-62. (PMID: 34716918)
J Manag Care Spec Pharm. 2019 Nov;25(11):1174-1181. (PMID: 31535596)
Int J Environ Res Public Health. 2020 Nov 10;17(22):. (PMID: 33182732)
Health Policy. 2018 Mar;122(3):217-229. (PMID: 29223847)
BMC Health Serv Res. 2010 Jun 07;10:153. (PMID: 20529296)
Pharmacoeconomics. 2019 Dec;37(12):1469-1483. (PMID: 31535280)
Health Policy. 2018 May;122(5):528-532. (PMID: 29567205)
Soc Sci Med. 2015 Jan;124:39-47. (PMID: 25461860)
Regen Med. 2021 Apr;16(4):405-422. (PMID: 33847163)
Front Med (Lausanne). 2022 Aug 12;9:940371. (PMID: 36035424)
Value Health. 2019 Jun;22(6):642-647. (PMID: 31198180)
Lancet. 2017 Jan 28;389(10067):403-476. (PMID: 27832874)
Am J Manag Care. 2015 Sep;21(9):632-40. (PMID: 26618366)
Orphanet J Rare Dis. 2013 Dec 24;8:198. (PMID: 24365263)
J Pharm Policy Pract. 2020 Jul 16;13:22. (PMID: 32695425)
Front Pharmacol. 2020 Dec 08;11:594446. (PMID: 33363468)
Pharmacoeconomics. 2020 Nov;38(11):1165-1185. (PMID: 32734573)
Health Policy. 2010 Aug;96(3):179-90. (PMID: 20226559)
Int J Technol Assess Health Care. 2022 Mar 11;38(1):e23. (PMID: 35274602)
Int J Technol Assess Health Care. 2021 Jan 29;37:e31. (PMID: 33509311)
Health Aff (Millwood). 2011 Dec;30(12):2329-37. (PMID: 22147861)
Health Policy. 2020 Apr;124(4):404-410. (PMID: 32093981)
Value Health. 2013 Jul-Aug;16(5):703-19. (PMID: 23947963)
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. (PMID: 28063134)
Value Health. 2019 Apr;22(4):399-407. (PMID: 30975390)
Front Med (Lausanne). 2022 Sep 23;9:940886. (PMID: 36213666)
Pharmacoeconomics. 2017 Dec;35(12):1271-1285. (PMID: 28836222)
Adm Policy Ment Health. 2015 Sep;42(5):533-44. (PMID: 24193818)
Front Pharmacol. 2017 Apr 04;8:171. (PMID: 28420990)
Drug Discov Today. 2023 Jan;28(1):103433. (PMID: 36372328)
Int J Technol Assess Health Care. 2021 Aug 23;37(1):e83. (PMID: 34424152)
Pharmacoeconomics. 2022 Jan;40(1):13-29. (PMID: 34480324)
BMJ. 2017 Oct 4;359:j4530. (PMID: 28978555)
J Manag Care Spec Pharm. 2017 Oct;23(10):1018-1026. (PMID: 28944734)
J Mark Access Health Policy. 2015 Sep 30;3:. (PMID: 27123175)
فهرسة مساهمة: Keywords: delayed payment models; health technology assessment; managed entry agreements; outcome-based reimbursement; pharmaceutical reimbursement; stakeholder perspectives
تواريخ الأحداث: Date Created: 20230108 Date Completed: 20230110 Latest Revision: 20230308
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9819658
DOI: 10.3390/ijerph20010340
PMID: 36612665
قاعدة البيانات: MEDLINE
الوصف
تدمد:1660-4601
DOI:10.3390/ijerph20010340